PTEN and prostate carcinoma: Although two studies show that PTEN-deficient endometrial tumor cells are not sensitive to PARPi monotherapy [37,77], we observe that PTEN-deficient GBM cell lines are somewhat attenuated with olaparib treatment; observations more consistent with the studies performed on PTEN-deficient prostate cancer cell lines [35].